147 related articles for article (PubMed ID: 1569814)
41. Evaluation of a new fixed duration (12 weeks) multi-drug regimen of bactericidal drugs in multibacillary leprosy.
Tejasvi T; Khaitan BK; Khanna N; Pandhi RK; Singh MK
Indian J Lepr; 2006; 78(4):329-37. PubMed ID: 17402345
[TBL] [Abstract][Full Text] [Related]
42. [Field experiences with therapy protocols in leprosy].
Pattyn SR
Verh K Acad Geneeskd Belg; 1983; 45(3):303-14. PubMed ID: 6364614
[No Abstract] [Full Text] [Related]
43. Evaluation of multi-drug therapy for leprosy in the United States using daily rifampin.
Dacso MM; Jacobson RR; Scollard DM; Stryjewska BM; Prestigiacomo JF
South Med J; 2011 Oct; 104(10):689-94. PubMed ID: 21941157
[TBL] [Abstract][Full Text] [Related]
44. Effect of clofazimine and dapsone on rifampicin (Lositril) pharmacokinetics in multibacillary and paucibacillary leprosy cases.
Mehta J; Gandhi IS; Sane SB; Wamburkar MN
Indian J Lepr; 1985; 57(2):297-310. PubMed ID: 4078356
[TBL] [Abstract][Full Text] [Related]
45. Therapeutic efficacy of benzoxazinorifamycin, KRM-1648, in combination with other antimicrobials against Mycobacterium leprae infection induced in nude mice.
Saito H; Tomioka H; Sato K; Dekio S
Int J Lepr Other Mycobact Dis; 1994 Mar; 62(1):43-7. PubMed ID: 8189088
[TBL] [Abstract][Full Text] [Related]
46. Treatment of leprosy.
Kar HK; Gupta R
Clin Dermatol; 2015; 33(1):55-65. PubMed ID: 25432811
[TBL] [Abstract][Full Text] [Related]
47. Dapsone drug resistance in the MDT era.
Roche PW; Neupane KD; Failbus SS; Butlin CR
Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):323-5. PubMed ID: 11221097
[No Abstract] [Full Text] [Related]
48. [Immuno-allergic accidents with rifamipcin].
Flageul B; Wagner L; Cottenot F
Acta Leprol; 2001-2002; 12(2):71-8. PubMed ID: 12136739
[TBL] [Abstract][Full Text] [Related]
49. Evaluation of Prospective HLA-B*13:01 Screening to Prevent Dapsone Hypersensitivity Syndrome in Patients With Leprosy.
Liu H; Wang Z; Bao F; Wang C; Sun L; Zhang H; Yu G; Mi Z; Li J; Li L; Zhao Q; Yue Z; Zhao W; Yu W; Cao J; Xiong F; Wang Y; Chai Z; Cheng X; Zhang Y; Fu F; Lang X; Wang X; Irwanto A; Krismawati H; Fu X; Sun Y; You J; Liu J; Pan Q; Chu T; Liu D; Chen S; Shen J; Yan L; Zhang G; Liu J; Zhang F; ; Xiong L; Yang J; Li J; Ke W; Li M; Ning Y; Xiong J; Li M; Xiong M; Yang B; Duan Q; Wang H; Li W; Kuang Y; Li J; Wang L; Cao Q; Xiao P; Xiao B; Zhang L; Lin Z; Wang Y; Shen Y; Yan L; Wu W; Zheng H; Zhan X; Li W; Shang X; Xu Y; Liu Q
JAMA Dermatol; 2019 Jun; 155(6):666-672. PubMed ID: 30916737
[TBL] [Abstract][Full Text] [Related]
50. [New WHO recommendations for the treatment of leprosy].
Acta Leprol; 1997; 10(4):189. PubMed ID: 9527754
[No Abstract] [Full Text] [Related]
51. [Acceptability, compliance and tolerance of daily polychemotherapy by leprosy patients in Guadeloupe].
Cartel JL; Gallais JJ; Grosset JH
Acta Leprol; 1985; 3(4):339-55. PubMed ID: 3913270
[TBL] [Abstract][Full Text] [Related]
52. Comparison of DDS with two combined chemotherapy regimens for multibacillary leprosy. Results after 3 years of treatment. A prospective randomized multicentre study.
Dietrich M; Wabitsch R
Lepr Rev; 1986; 57 Suppl 3():60-2. PubMed ID: 3573962
[No Abstract] [Full Text] [Related]
53. Hemolytic anemia in patients receiving daily dapsone for the treatment of leprosy.
Deps P; Guerra P; Nasser S; Simon M
Lepr Rev; 2012 Sep; 83(3):305-7. PubMed ID: 23356031
[TBL] [Abstract][Full Text] [Related]
54. Methemoglobinemia and dapsone levels in patients with leprosy.
Vieira JL; Riveira JG; Martins Ade N; Silva JP; Salgado CG
Braz J Infect Dis; 2010; 14(3):319-21. PubMed ID: 20835521
[TBL] [Abstract][Full Text] [Related]
55. Dapsone syndrome with acute renal failure during leprosy treatment: case report.
Alves-Rodrigues EN; Ribeiro LC; Silva MD; Takiuchi A; Fontes CJ
Braz J Infect Dis; 2005 Feb; 9(1):84-6. PubMed ID: 15947852
[TBL] [Abstract][Full Text] [Related]
56. Adverse effects from multi-drug therapy in leprosy: a Brazilian study.
Deps PD; Nasser S; Guerra P; Simon M; Birshner Rde C; Rodrigues LC
Lepr Rev; 2007 Sep; 78(3):216-22. PubMed ID: 18035772
[TBL] [Abstract][Full Text] [Related]
57. Adverse effects of alternative therapy (minocycline, ofloxacin, and clofazimine) in multibacillary leprosy patients in a recognized health care unit in Manaus, Amazonas, Brazil.
Maia MV; Cunha Mda G; Cunha CS
An Bras Dermatol; 2013; 88(2):205-10. PubMed ID: 23739719
[TBL] [Abstract][Full Text] [Related]
58. Developing new MDT regimens for MB patients; time to test ROM 12 month regimens globally.
Lockwood DN; Cunha Mda G
Lepr Rev; 2012 Sep; 83(3):241-4. PubMed ID: 23356024
[No Abstract] [Full Text] [Related]
59. On multi-drug combinations in the treatment of leprosy.
Chatterjee BR
Indian J Lepr; 1988 Oct; 60(4):493-8. PubMed ID: 3253329
[No Abstract] [Full Text] [Related]
60. Evaluation of multidrug therapy with rifampicin, clofazimine and D.D.S. in multibacillary leprosy cases.
Kundu SK; Hazra SK; Chaudhury S; Chatterjee B
Indian J Lepr; 1984; 56(1):78-85. PubMed ID: 6548246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
